About Eukaryotic peptide chain release factor subunit 1
Eukaryotic peptide chain release factor subunit 1 (ETF1) is a protein
from Homo sapiens identified by UniProt accession
P62495, 437 residues long.
MolForge cross-references it against 0 known binders and
40 disease associations.
Target properties
| Protein name | Eukaryotic peptide chain release factor subunit 1 |
| UniProt accession | P62495 |
| Gene | ETF1 |
| Organism | Homo sapiens |
| Length | 437 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (40)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- schizophrenia · score 0.30
- erythrocyte count · score 0.24
- red blood cell density measurement · score 0.21
- asthma · score 0.18
- risk-taking behaviour · score 0.14
- autism spectrum disorder · score 0.07
- mean corpuscular hemoglobin · score 0.05
- mean corpuscular hemoglobin concentration · score 0.04
- infection · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P62495-F1 | alphafold | PREDICTED | 85.06 | — |
Amino-acid sequence (437 residues)
MADDPSAADR NVEIWKIKKL IKSLEAARGN GTSMISLIIP PKDQISRVAK MLADEFGTAS NIKSRVNRLS VLGAITSVQQ RLKLYNKVPP NGLVVYCGTI VTEEGKEKKV NIDFEPFKPI NTSLYLCDNK FHTEALTALL SDDSKFGFIV IDGSGALFGT LQGNTREVLH KFTVDLPKKH GRGGQSALRF ARLRMEKRHN YVRKVAETAV QLFISGDKVN VAGLVLAGSA DFKTELSQSD MFDQRLQSKV LKLVDISYGG ENGFNQAIEL STEVLSNVKF IQEKKLIGRY FDEISQDTGK YCFGVEDTLK ALEMGAVEIL IVYENLDIMR YVLHCQGTEE EKILYLTPEQ EKDKSHFTDK ETGQEHELIE SMPLLEWFAN NYKKFGATLE IVTDKSQEGS QFVKGFGGIG GILRYRVDFQ GMEYQGGDDE FFDLDDY
Explore Eukaryotic peptide chain release factor subunit 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets